B
Brad S. Kahl
Researcher at Washington University in St. Louis
Publications - 470
Citations - 19772
Brad S. Kahl is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Rituximab & Mantle cell lymphoma. The author has an hindex of 56, co-authored 404 publications receiving 16236 citations. Previous affiliations of Brad S. Kahl include Jagiellonian University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts,Matthew S. Davids,John M. Pagel,Brad S. Kahl,Soham D. Puvvada,John F. Gerecitano,Thomas J. Kipps,Mary Ann Anderson,Mary Ann Anderson,Jennifer R. Brown,Lori A. Gressick,Shekman Wong,Martin Dunbar,Ming Zhu,Monali Desai,Elisa Cerri,Sari H. Enschede,Rod A. Humerickhouse,William G. Wierda,John F. Seymour,John F. Seymour +20 more
TL;DR: Selective targeting of BCL2 with venetoclax had a manageable safety profile and induced substantial responses in patients with relapsed CLL or SLL, including those with poor prognostic features.
Journal ArticleDOI
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang,Simon Rule,Peter Martin,Andre Goy,Rebecca Auer,Brad S. Kahl,Brad S. Kahl,Wojciech Jurczak,Ranjana H. Advani,Jorge E. Romaguera,Michael E. Williams,Jacqueline C. Barrientos,Ewa Chmielowska,John Radford,Stephan Stilgenbauer,Martin Dreyling,Wiesław Wiktor Jędrzejczak,Peter Johnson,Stephen E. Spurgeon,Lei Li,Liang Zhang,Kate J. Newberry,Zhishuo Ou,Nancy Cheng,Bingliang Fang,Jesse McGreivy,Fong Clow,Joseph J. Buggy,Betty Y. Chang,Darrin M. Beaupre,Lori Kunkel,Kristie A. Blum +31 more
TL;DR: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma and is enrolled into two groups: patients who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles.
Journal ArticleDOI
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal,Ajay K. Gopal,Brad S. Kahl,Sven de Vos,Nina D. Wagner-Johnston,Stephen J. Schuster,Wojciech Jurczak,Ian W. Flinn,Christopher R. Flowers,Peter Martin,Andreas Viardot,Kristie A. Blum,Andre Goy,Andrew Davies,Pier Luigi Zinzani,Martin Dreyling,Dave Johnson,Langdon L. Miller,Leanne Holes,Daniel Li,Roger Dansey,Wayne R. Godfrey,Gilles Salles +22 more
TL;DR: In this single-group, open-label, phase 2 study, idelalisib showed antitumor activity with an acceptable safety profile in patients with indolent non-Hodgkin's lymphoma who had received extensive prior treatment.
Journal ArticleDOI
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Richard I. Fisher,Steven H. Bernstein,Brad S. Kahl,Benjamin Djulbegovic,Michael J. Robertson,Sven de Vos,Elliot M. Epner,Amrita Krishnan,John P. Leonard,Sagar Lonial,Edward A. Stadtmauer,Owen A. O'Connor,Hongliang Shi,Anthony Boral,Andre Goy +14 more
TL;DR: Bortezomib provides significant clinical activity in terms of durable and complete responses, and may represent a new treatment option for this population with usually very poor outcome.
Journal ArticleDOI
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.
Jennifer R. Brown,John C. Byrd,Steven Coutre,Don M. Benson,Ian W. Flinn,Nina D. Wagner-Johnston,Stephen E. Spurgeon,Brad S. Kahl,Celeste M. Bello,Heather K. Webb,Dave Johnson,Sissy Peterman,Daniel Li,Thomas Jahn,Brian J. Lannutti,Roger G. Ulrich,Albert S. Yu,Langdon L. Miller,Richard R. Furman +18 more
TL;DR: The clinical utility of inhibiting the PI3Kδ pathway with idelalisib is demonstrated and the findings support the further development of idELalisib in patients with CLL.